Global Respiratory Virus Vaccines Market to Surpass a Valuation of US$ 14 Bn by 2030

Fact.MR

Incessantly rising demand in response to the unbridled spread of COVID-19 has pushed the respiratory virus vaccines market to the fore. Fact MR’s recent study on the market is intended to offer insights into the future and discover hidden opportunities for market players. Increasing R&D investments and initiatives are aiding exponential growth in the market.

For detailed insights on enhancing your product footprint, request for a sample here – https://www.factmr.com/connectus/sample?flag=S&rep_id=5199

Considering that the aforementioned trend will show no signs of slowing down, Fact.MR projects the market to rise at an 8% CAGR from 2020 and 2030. With some prominent international organizations increasing their funding towards research & development, the market is expected to gain significant impetus over the coming years. For instance, the National Institute of Allergy and Infectious Diseases (NIAID) has recently announced a funding of US$ 51 Mn towards the Collaborative Influenza Vaccine Innovation Centers (CIVICs) program, with the intention of developing influenza vaccines.

Key Takeaways from Respiratory Virus Vaccines Market Study

  • The global respiratory virus vaccines market is expected to surpass a valuation of US$ 14 Bn by 2030.
  • North America currently dominates the global market for respiratory virus vaccines.
  • Based on type, inactivated/ killed vaccines’ hegemony will continue through 2030.
  • Based on indication, demand from the influenza segment will remain comparatively higher.
  • Among all the age groups, demand from the pediatric segment is likely to be higher.
  • Physician offices are currently dominating among the end users.

For critical insights on this market, request for methodology here – https://www.factmr.com/connectus/sample?flag=RM&rep_id=5199

“Demand witnessed in the respiratory virus vaccines market is forecast to surge especially on account of the unprecedented outbreak of COVID-19. An increasing number of market players are expected to focus on research initiatives, to gain a competitive advantage in this space,” says a Fact.MR analyst.

Rising Burden of Respiratory Illnesses Fuelling Demand

According to the World Health Organization, nearly 290,000 to 650,000 people die every year around the world due to flu-related illnesses. Rising incidence of respiratory illnesses and subsequently increasing demand for vaccines to prevent respiratory infections are the chief drivers of the global market.

With leading pharmaceutical companies racing to be the first to develop and launch a vaccine for the novel coronavirus, the respiratory virus vaccines market is expected to surge exponentially through the course of the forecast period.

For comprehensive insights on this market adoption, ask an analyst here – https://www.factmr.com/connectus/sample?flag=AE&rep_id=5199

Government Initiatives to Make Vaccines Better Accessible

Governments around the world are adopting various initiatives to curb incidence of chronic ailments. They are also funding researches on vaccination programs and overall expansion of the healthcare sector, which is expected to enable growth in the market.

For instance, in April 2017, the Government of Canada announced its plans of investing C$ 1.7 Mn in the Immunization Partnership Fund. Through this, it intended to fund various projects on improving vaccination coverage across Canada.

About Us:

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.

Contact:

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Email: sales@factmr.com
Visit Our Website: https://www.factmr.com

Matched content

Editor’s pick

Express Press Release Distribution
The entire EPR Network is up for sale!
This is default text for notification bar